Patents by Inventor Jorge Alsina-Fernandez

Jorge Alsina-Fernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210032299
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 29, 2020
    Publication date: February 4, 2021
    Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
  • Patent number: 10894817
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt of the Formula: X1IVX2SLDVPIGLLQILX3EQEKQEKEKQQAK*TNAX4ILAQV-NH2 wherein the X1 denotes that the I residue is modified by either acetylation or methylation at the N-terminus; wherein X2 is L or T; wherein X3 is L or I; wherein X4 is Q or E; and wherein a modified K residue (“K*”) at position 29 is modified through conjugation to the epsilon-amino group of the K-side chain with a group of the formula —X5—X6, wherein X5 is selected from the group consisting of one to four amino acids; one to four ([2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties; and combinations of one to four amino acids and one to four ([2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties; and X6 is a C14-C24 fatty acid. In some embodiments, the group of the formula —X5—X6 is ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(?E)2-CO—(CH2)x—CO2H where x is 16 or 18.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: January 19, 2021
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Lili Guo, John Lee
  • Publication number: 20200331980
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
    Type: Application
    Filed: December 14, 2018
    Publication date: October 22, 2020
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Publication number: 20200024322
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Kyle Wynn Sloop, Francis Stafford Willard, Thi Thanh Huyen Tran, Aktham Aburub, Phenil Jayantilal Patel, Amita Datta-Mannan, Xianyin Lai
  • Publication number: 20180104312
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Application
    Filed: December 22, 2017
    Publication date: April 19, 2018
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • Patent number: 9884093
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: February 6, 2018
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • Publication number: 20180016318
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt of the Formula: X1IVX2SLDVPIGLLQILX3EQEKQEKEKQQAK*TNAX4ILAQV-NH2 wherein the X1 denotes that the I residue is modified by either acetylation or methylation at the N-terminus; wherein X2 is L or T; wherein X3 is L or I; wherein X4 is Q or E; and wherein a modified K residue (“K*”) at position 29 is modified through conjugation to the epsilon-amino group of the K-side chain with a group of the formula —X5—X6, wherein X5 is selected from the group consisting of one to four amino acids; one to four ([2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties; and combinations of one to four amino acids and one to four ([2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties; and X6 is a C14-C24 fatty acid. In some embodiments, the group of the formula —X5—X6 is ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(?E)2-CO—(CH2)x—CO2H where x is 16 or 18.
    Type: Application
    Filed: July 13, 2017
    Publication date: January 18, 2018
    Inventors: Jorge Alsina-Fernandez, Lili Guo, John Lee
  • Patent number: 9764004
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 19, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • Patent number: 9695225
    Abstract: A peptide compound useful in the treatment of hypoglycemia is described.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: July 4, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • Patent number: 9688736
    Abstract: A peptide compound useful in the treatment of hypoglycemia is described.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 27, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins
  • Publication number: 20170114115
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 27, 2017
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • Publication number: 20170112904
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 27, 2017
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • Publication number: 20160311882
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • Publication number: 20160311881
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • Publication number: 20160311883
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins
  • Patent number: 9474780
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: October 25, 2016
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • Publication number: 20160199438
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Application
    Filed: January 5, 2016
    Publication date: July 14, 2016
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • Patent number: 8815811
    Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: August 26, 2014
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Krister Bengt Bokvist, Lili Guo, John Philip Mayer
  • Publication number: 20140056893
    Abstract: This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 27, 2014
    Applicant: Eli Lilly and Company
    Inventors: Tamer Coskun, Ryan James Darling, Malgorzata Donata Gonciarz, Jorge Alsina-Fernandez
  • Patent number: 8415296
    Abstract: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: April 9, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Wayne David Kohn